Managing Pneumonitis Following Immune Checkpoint Inhibition in Kidney Cancer
Raja E. Abdulnour, MD, discusses modern management strategies for pneumonitis induced by treatment with immune checkpoint inhibitors in patients with kidney cancer.
Raja E. Abdulnour, MD, a pulmonologist in the Division of Pulmonary and Critical Care Medicine at Brigham and Women's Hospital, discusses modern management strategies for pneumonitis caused by treatment with immune checkpoint inhibitors, in patients with kidney cancer.
Immune checkpoint inhibitor-induced pneumonitis is defined as the development of sudden or chronic respiratory toxicity along with inflammation in the lung, in patients who do not have other reasons for these toxicities, other than their treatment. An infection, disease progression, and heart failure are examples of other issues that may cause toxicities. Once immune checkpoint inhibitor-induced pneumonitis has been confirmed, is it safe to begin managing the pneumonitis.
Treatment for pneumonitis depends on the severity. For patients who require oxygen, the typical treatment is steroids, which help with inflammation. If the steroids work, then patients are given multi-week cycles of prednisone, a corticosteroid.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
